Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2011

View Archived Issues

AstraZeneca divulges novel DAT and NET ligands

Suven Life Sciences' histamine H3 receptor antagonist reverses cognitive deficits in vivo

New irreversible epidermal growth factor receptor inhibitor shows preclinical antitumor activity

Sanofi claims new tryptase beta inhibitors

Galderma discloses novel androgen receptor antagonists

Chinese university presents new antitumor noscapine derivatives

Bayer Schering Pharma patents novel apoptosis imaging agents

Idenix identifies new anti-HCV agents

Phase IV data presented on maraviroc in pediatric patients with CCR5-tropic HIV-1 infection

Results presented from first trial evaluating DNA vaccine for HIV in children

GABA(A) receptor inverse agonist exhibits procognitive effects in vivo

Pfizer signs agreement to acquire Icagen

AMAG Pharmaceuticals and Allos Therapeutics advance plans to merge

Valeant enters into agreement for Canadian marketing and distribution rights to Zuacta

Dynavax reports topline phase III data on Heplisav versus Engerix-B

Pharmasset announces new data from phase IIb PSI-7977 trial

FDA clears trial of intranasal Ampligen with seasonal influenza vaccine

FDA places clinical hold on phase II IMO-3100 trial

MundiPharma to launch Norspan tape in Japan in August

SuperGen acquires Astex Therapeutics

Japanese Lexapro launch scheduled for next month

AstraZeneca's Brilinta approved in U.S.

Taiho and Nordic Group to collaborate on Teysuno

First patient enrolled in NCI's pediatric phase I trial of Marqibo

Single-vial Taxotere formulation launched in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...